Citius Pharmaceuticals, Inc.
-$31.69M- Market cap
- $16.13M
- Debt
- +-$6.11M
- Cash
- −$41.71M
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: CTXR stock price at premium vs OGE $0.59 current versus $0.01 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at OGE's multiple
Implied fair value · at CTXR's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CTXR FY 2022 (ended Sep 30, 2022) · OGE FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
13 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
Capital structure 63% equity / 37% debt · EV / Revenue 4.71x · EV / EBITDA 9.95x
OGE carries the larger enterprise value at $15.34B against -$31.69M; CTXR trades on the lower EV / EBITDA multiple (0.96x vs 9.95x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
OGE ENERGY CORP. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.06x
1.14x
Net debt / EBITDA
Leverage against operating earnings
1.45x
3.67x
Cash and equivalents
Liquid reserves on the balance sheet
$41.71M
$200.00K
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zomedica Corp.
CTXR vs ZOM
Aquestive Therapeutics, Inc.
CTXR vs AQST
ACADIA PHARMACEUTICALS INC
CTXR vs ACAD
AMGEN INC
CTXR vs AMGN
GILEAD SCIENCES, INC.
CTXR vs GILD
AbbVie Inc.
CTXR vs ABBV
CENTERPOINT ENERGY INC
CTXR vs CNP
ALLIANT ENERGY CORP
CTXR vs LNT
AMERICAN ELECTRIC POWER CO INC
CTXR vs AEP
XCEL ENERGY INC
CTXR vs XEL
Evergy, Inc.
CTXR vs EVRG
PINNACLE WEST CAPITAL CORP
CTXR vs PNW
-$6.11M
$5.66B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.